v3.26.1
Commitments and Contingencies (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Dec. 29, 2023
Aug. 31, 2023
Aug. 31, 2022
Oct. 31, 2019
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Aug. 31, 2025
Jul. 05, 2025
Nov. 06, 2023
Nov. 15, 2022
Oct. 31, 2021
Jan. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Accounts payable         $ 1,888,729 $ 1,467,052                
Loss on legal settlement       $ 267,680                    
Repayments of related party debt             $ 146,912              
Settlement expense   $ 38,838                        
Final payment resolved         135,000                  
Number of shares of common stock     360,000                      
Warrants to purchase shares           247,500                
Warrants exercise price           $ 0.75                
Court Officer [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Repayments of notes payable               $ 103,088            
Deposit               $ 250,000            
Promissory Note [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Notes payable, principal amount                           $ 250,000
Sponsored Research Agreement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Budget research expense                 $ 296,000 $ 327,000 $ 1,296,000 $ 1,300,000 $ 1,300,000  
Yeda Research and License Agreement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Research and development expenses         58,000 $ 58,000                
Accrued liabilities current         130,500 72,500                
MD Anderson Sponsored Research Agreements [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Research and development expenses         1,759,872 1,406,193                
Accrued liabilities current         16,545                  
Accounts payable         $ 1,189,372                  
Settlement Agreement [Member]                            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                            
Loss on legal settlement           $ 142,600                
Number of shares of common stock 180,000                          
Warrants to purchase shares 180,000                          
Warrants exercise price $ 0.75                          
Convertible promissory note $ 50,000